Objective To explore the therapeutic effects of tacrolimus combined with low-dose hormone in the treatment of IgA nephropathy. Methods: A total of 70 patients with IgA nephropathy who were admitted to our hospital from June 2021 to June 2022 were divided into a control group (low-dose hormone treatment, n=35 cases) and a research group (tacrolimus combined with low-dose hormone treatment, n=35 cases) according to the random number table. The clinical treatment effects of the two groups were compared, and the renal function indexes before and after treatment were measured. Finally, the adverse reactions of the patients were observed and recorded. Results The overall effective rate of treatment in research group was 94.29％, which was higher than that in control group (P＜0.05). After treatment, the 24-h urine protein, Scr, BUN and Cys-C levels of patients in the research group were (1.06±0.23) g, (87.51±9.63) μ mol/L, (6.23±0.83) mmol/L and (0.62±0.10)mg/L/L, all lower than those in the control group (P＜0.05). The incidence rate of adverse drug reactions in patients of the study group was 28.57％, and there was no statistical difference as compared with the adverse reaction rate in the control group (P＞0.05). Conclusion: The combined use of tacrolimus and low-dose hormones in the treatment of IgA nephropathy has an ideal effect. It can significantly reduce the amount of 24h urine protein in patients and improve their renal function. At the same time, it does not significantly increase the adverse drug reactions, which is worthy of promotion.
关键词
IgA肾病/他克莫司/小剂量激素/肾功能/不良反应
Key words
IgA nephropathy/Tacrolimus/Low dose hormone/renal function/adverse effect
万方数据